Schizophrenia Drugs Industry

The global schizophrenia drugs market is projected to reach USD 11.20 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are expected to drive the growth of the market, including advancements in drug delivery technologies, the increasing availability of Long-Acting Injectables (LAIs), and a rising number of patients seeking treatment. Key features that are expected to drive the adoption of novel schizophrenia drugs include a fast onset of action, improved accessibility for patients, high efficiency, and enhanced patient compliance, which are likely to facilitate market penetration.

Schizophrenia remains a significant burden on patients, their families, and society at large, both from a health and socioeconomic perspective. As awareness of mental health issues, particularly schizophrenia, continues to increase among patients and healthcare providers, there is likely to be greater adoption of existing and new treatments. Currently, second and third-generation antipsychotic medications capture a substantial share of the market. These drugs are more effective and have better side-effect profiles than older medications, offering a more favorable treatment option for patients.

Moreover, several pipeline drugs that are currently undergoing clinical trials aim to target specific subtypes of serotonin and dopamine receptors. By focusing on these receptors, these drugs aim to minimize the symptoms of schizophrenia, modulate elevated dopamine levels, and improve cognitive functions such as memory. These advancements promise to further enhance the quality of life for schizophrenia patients and have the potential to expand the market.

The growth of the schizophrenia market is anticipated to be driven largely by the arrival of late-stage pipeline products such as Intra-Cellular Therapies’ ITI-007 and Alkermes’ ALKS-3831. These drugs are focused on treating the negative symptoms of schizophrenia, a key area of unmet need in the current treatment landscape. However, significant challenges remain, such as the incomplete understanding of the disease’s exact mechanisms, which hinders the development of truly breakthrough therapies. As a result, there is a pressing need for continued innovation, particularly in drug delivery technologies, to address these challenges and better manage this debilitating disorder.

Curious about the Schizophrenia Drugs Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Schizophrenia Drugs Market Segments Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.0% in 2023. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2023. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2023. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 39.0% in 2023. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Schizophrenia Drugs Market Report Segmentation

Grand View Research has segmented the global schizophrenia drugs market based on class, treatment, distribution channel, and region:

Schizophrenia Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Second-Generation Antipsychotics          
    • Risperdal (Risperidone)
    • Invega (Paliperidone)
    • Zyprexa (Olanzapine)
    • Geodon (Ziprasidone)
    • Seroquel (Quetiapine)
    • Latuda (Lurasidone)
    • Aristada (Aripiprazole Lauroxil)
    • Fanapt (Iloperidone)
    • Saphris (Asenapine)
    • Vraylar (Cariprazine)
  • Third-Generation Antipsychotics              
    • Abilify (Aripiprazole)
  • Others 
    • First-Generation Antipsychotics
    • Generics

Schizophrenia Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral Antipsychotics
  • Injectable Antipsychotics

Schizophrenia Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Schizophrenia Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • Kuwait
    • South Africa

Key Schizophrenia Drugs Company Insights

  • Johnson & Johnson
  • Bristol-Myers Squibb/ Otsuka Pharma
  • AstraZeneca
  • Sumitomo Dainippon
  • Eli Lilly & Company
  • Alkermes
  • Vanda Pharma
  • Allergan
  • Pfizer
  • Lundbeck A/S

Order a free sample PDF of the Schizophrenia Drugs Market Intelligence Study, published by Grand View Research.